Summary
Global Markets Direct’s, ‘Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2016’, provides in depth analysis on Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted pipeline therapeutics.
The report provides comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Bristol-Myers Squibb Company
Enumeral Biomedical Holdings, Inc.
GlaxoSmithKline Plc
Incyte Corporation
MacroGenics, Inc.
Novartis AG
Regeneron Pharmaceuticals, Inc.
Sutro Biopharma, Inc.
Symphogen A/S
Tesaro, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Overview 7
Therapeutics Development 8
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Stage of Development 8
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Therapy Area 9
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Indication 10
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Companies 14
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development 22
Bristol-Myers Squibb Company 22
Enumeral Biomedical Holdings, Inc. 23
GlaxoSmithKline Plc 24
Incyte Corporation 25
MacroGenics, Inc. 26
Novartis AG 27
Regeneron Pharmaceuticals, Inc. 28
Sutro Biopharma, Inc. 29
Symphogen A/S 30
Tesaro, Inc. 31
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles 32
BMS-986016 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ENUM-006 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GSK-2831781 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
IMP-701 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
IMP-731 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
LAG-525 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
MGD-013 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TSR-033 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Projects 47
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Featured News & Press Releases 48
Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016 48
Jan 27, 2016: US Patent Grants for IMP731 Antibody 48
Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program 48
Jan 28, 2015: Prima BioMed to Receive Financial Milestone Payment From GSK 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51
List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Bristol-Myers Squibb Company, H2 2016 22
Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016 23
Pipeline by GlaxoSmithKline Plc, H2 2016 24
Pipeline by Incyte Corporation, H2 2016 25
Pipeline by MacroGenics, Inc., H2 2016 26
Pipeline by Novartis AG, H2 2016 27
Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016 28
Pipeline by Sutro Biopharma, Inc., H2 2016 29
Pipeline by Symphogen A/S, H2 2016 30
Pipeline by Tesaro, Inc., H2 2016 31
Dormant Projects, H2 2016 47
List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 20
